Condition: Melanoma Stage Iv · Sponsor: Melanoma Institute Australia
This is a phase II, open label, randomised trial of ipilimumab and nivolumab with concurrent intracranial stereotactic radiotherapy versus ipilimumab and nivolumab alone in patients with asymptomatic, untreated melanoma brain metastases.
This description comes directly from the study's public registry record.
Georgina V Long, MBBS PhD · +61 2 9911 7200 · info@melanoma.org.au
Maria Gonzalez, RN MHSc · +61 2 9911 7200 · maria.gonzalez@melanoma.org.au
Always discuss trial participation with your own doctor first.
| Westmead Hospital | Sydney, New South Wales, Australia | Recruiting |
| Calvary Mater NewcastleHospital | Waratah, New South Wales, Australia | Recruiting |
| Melanoma Institute Australia | Wollstonecraft, New South Wales, Australia | Recruiting |
| Princess Alexandra Hospital | Woolloongabba, Queensland, Australia | Recruiting |
| Royal Adelaide Hospital | Adelaide, South Australia, Australia | Recruiting |
| Peter MacCallum Cancer Centre | East Melbourne, Victoria, Australia | Recruiting |
| Alfred Hospital | Melbourne, Victoria, Australia | Recruiting |
| Sir Charles Gairdner Hosptial | Perth, Western Australia, Australia | Recruiting |
| Oslo Univesity Hospital Radiumhospitalet | Oslo, Oslo, Norway | Terminated |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03340129